P. Colin

464 total citations
15 papers, 352 citations indexed

About

P. Colin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, P. Colin has authored 15 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Otorhinolaryngology. Recurrent topics in P. Colin's work include Colorectal Cancer Treatments and Studies (5 papers), Head and Neck Cancer Studies (4 papers) and Gastric Cancer Management and Outcomes (4 papers). P. Colin is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Head and Neck Cancer Studies (4 papers) and Gastric Cancer Management and Outcomes (4 papers). P. Colin collaborates with scholars based in France, United States and Spain. P. Colin's co-authors include Jean-Michel Vannetzel, Susan Shott, S G Taylor, Everett E. Vokes, James C. Hutchinson, John Showel, Anantha Murthy, Thierry André, Emmanuel Achille and Pascal Piedbois and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Journal of Cancer.

In The Last Decade

P. Colin

13 papers receiving 341 citations

Peers

Countries citing papers authored by P. Colin

Since Specialization

Citations

This map shows the geographic impact of P. Colin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Colin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Colin more than expected).

Fields of papers citing papers by P. Colin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Colin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Colin. The network helps show where P. Colin may publish in the future.

Co-authorship network of co-authors of P. Colin

This figure shows the co-authorship network connecting the top 25 collaborators of P. Colin. A scholar is included among the top collaborators of P. Colin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Colin. P. Colin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC 2025 ·Journal of Thoracic Oncology ·(unknown), Pasi A. Jänne, (unknown), Bruna Pellini, Mohamed A. Khalil, C. Zhou, Takayasu Kurata, M. Shiller, Melissa L. Johnson, (unknown), Antonio Calles, (unknown), (unknown), P. Colin, Fabrice Barlési	0
2	Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1 2007 ·Journal of Clinical Oncology ·Thierry André, Emmanuel Quinaux, (unknown), P. Colin, E. Gamelin, Olivier Bouché, Emmanuel Achille, Pascal Piedbois, N. Tubiana-Mathieu, Arnaud Boutan-Laroze, (unknown), (unknown), (unknown), Isabelle Debrix, Marc Buyse, Aimery de Gramont	115
3	Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study 2006 ·Journal of Clinical Oncology ·P. Colin, Nicolas Jovenin, G. Ganem, (unknown), (unknown), F. Guichard, J Crétin, (unknown), (unknown), Jean‐François Morère	6
4	Treatment of pituitary adenomas by fractionated stereotactic radiotherapy (FSR). A prospective study of a cohort of 110 patients 2005 ·Neurochirurgie ·P. Colin, Nicolas Jovenin, Brigitte Delemer, J. Caron, H. Grulet, A.C. Hécart, (unknown), (unknown), A. Bazin, (unknown), B Scherpereel, P Peruzzi, (unknown), P. Rousseaux	1
5	5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer 2004 ·Journal of Clinical Oncology ·Arié Figer, (unknown), Élisabeth Carola, Thierry André, Isabel Chirivella, Gérard Lledo, M. Flesch, Fernando Rivera, P. Colin, Armand de Gramont	1
6	5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer 2004 ·Journal of Clinical Oncology ·Arié Figer, (unknown), Élisabeth Carola, Thierry André, Isabel Chirivella, Gérard Lledo, M. Flesch, Fernando Rivera, P. Colin, Armand de Gramont	10
7	Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminary safety results 2001 ·Seminars in Oncology ·Thierry André, P. Colin, (unknown), Érick Gamelin, Olivier Bouché, Emmanuel Achille, Nicolas Colbert, C Boaziz, Pascal Piedbois, N. Tubiana-Mathieu, Arnaud Boutan-Laroze, M. Flesch, (unknown), Marc Buyse	17
8	Folfiri then folfox of folfox then folfiri in metastatic colorectal cancer (MCRC): results of a phase III trial 2001 ·European Journal of Cancer ·Emmanuel Achille, Christophe Tournigand, Thierry André, Gérard Lledo, M. Flesch, G. Ganem, P. Colin, B. Landi, C. Couteau, Armand de Gramont	6
9	Prospective randomized study of mitoxantrone (M) and vinorelbine (V) vs fluorouracil (F), epirubicin (E) or adriamycin (A) and cyclophosphamide (C) in patients with advanced breast cancer (ABC) 1997 ·European Journal of Cancer ·F Turpin, D. Serin, G. Ganem, G. Calais, P. Maillart, P. Colin, Grégoire Prévost, (unknown), (unknown), P. Clavère, M. Namer	0
10	Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. 1997 ·Journal of Clinical Oncology ·G. Ganem, Bernard Dubray, (unknown), P. Colin, É. Bardet, J.-Y. Douillard, Marie-Josèphe Goudier, C. Hennequin, (unknown), (unknown), P. Martin, David J. Maron, F. Morvan, (unknown), Jean-Marc Extra	28
11	Evaluation of two dose individualisation methods for carboplatin. 1996 ·PubMed ·B Desoize, Robert Dufour, Saı̈k Urien, Matthieu L. Kaltenbach, P. Colin	4
12	104 The five year results of a randomized trial of sequential versus concomitant cisplatin and fluorouracil and radiation in advanced head and neck cancer 1995 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Anantha Murthy, J.M. Vannetzel, M.S. Kies, Bharat B. Mittal, John Showel, (unknown), (unknown), P. Colin, (unknown), Carol Blendowski, (unknown)	1
13	Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. 1994 ·Journal of Clinical Oncology ·S G Taylor, Anantha Murthy, Jean-Michel Vannetzel, P. Colin, (unknown), (unknown), Susan Shott, Everett E. Vokes, John Showel, James C. Hutchinson	155
14	Surgical restaging of advanced Hodgkin's disease after first line chemotherapy 1991 ·European Journal Of Haematology ·(unknown), Pauline Brice, E. Bourstyn, M F D'Agay, Éric Lepage, (unknown), Jean‐Paul Fermand, J.M. Extra, J Frija, P. Colin, (unknown)	2
15	Conventional megavoltage radiotherapy in the management of malignant epithelial tumours of the parotid gland 1989 ·Radiotherapy and Oncology ·Pascal Piedbois, J. P. Bataini, P. Colin, J.C. Durand, C Jaulerry, F Brunin, D. Pontvert	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact